Biotechnology · NASDAQ
当前价格
$745.77
内在价值
使用下方计算器估算
对 Regeneron Pharmaceuticals, Inc. 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Yield
5.87%
ROE (TTM)
14.8%
基于过去 12 个月的数据，REGN 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
REGN 的过去 12 个月市盈率为 可在计算器中查看。该估值指标反映投资者为 Regeneron Pharmaceuticals, Inc. 每一美元收益所支付的价格。使用 MiniValuator 的 PE 计算器进行详细分析。
REGN 是否被高估取决于将其市盈率与行业同类公司、历史均值和增长预期进行比较。高于行业平均的市盈率可能表明被高估，但高成长性公司通常有更高的市盈率。在 MiniValuator 上运行完整估值来分析。
使用市盈率对 REGN 估值：将其当前 PE 与行业平均值比较，分析 PEG 比率进行增长调整估值，查看历史 PE 区间，并通过目标 PE 乘以 EPS 估算公允价值。MiniValuator 的 PE 计算器可自动完成此分析。
REGN 的 PEG 比率为 可在计算器中查看。PEG 比率将市盈率除以盈利增长率——PEG 低于 1.0 可能表明股票相对于其增长被低估，是一个有用的辅助估值指标。
PE 市盈率提供快速的相对估值——REGN 与同类公司的比较。DCF 提供绝对估值——基于预期现金流的股票内在价值。建议同时使用两种方法进行综合估值。MiniValuator 同时提供 PE 和 DCF 计算器。
